Factor VIII treatment for severe hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is looking at the safety and effectiveness of a factor VIII medicine called octocog alfa (used to treat bleeding) in men with severe hemophilia A in India. It will track how well the medicine works and any side effects during routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male and at least 18 years old.
- You must have severe hemophilia A, meaning your factor VIII level is less than 1%.
- You must have been treated with factor VIII before, at least 100 times in total (for bleeds or prevention).
- Your doctor has decided to use octocog alfa (a factor VIII product) for on-demand treatment of bleeding episodes.
- You cannot be on regular preventive factor VIII or other non-factor treatments (like emicizumab).
- You must not have a history of factor VIII inhibitors or other bleeding disorders, and your liver/kidney/blood counts must be within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a medicine called damoctocog alfa pegol (Jivi) works to prevent bleeding in children with hemophilia A. It will follow children who are already using this medicine or starting it, to see how effective it is in real life.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This study looks at how many people with hemophilia A develop inhibitors (antibodies that stop factor VIII from working) after taking Coageight, a factor VIII medicine. It will help doctors understand how safe this treatment is for the long term.
This study looks at why the body sometimes stops responding to factor VIII treatment in hemophilia A. It aims to find patterns that help doctors predict and manage this, so they can keep the treatment working well.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.